New heart catheter aims to stop dangerous rhythms in their tracks
NCT ID NCT06703489
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study is testing a new device called the Sphere-9 catheter, used with the Affera mapping system, to treat ventricular tachycardia (VT) — a fast, dangerous heart rhythm. The procedure uses heat to destroy small areas of scarred heart tissue that cause the abnormal rhythm. The trial will enroll 60 adults who have had repeated episodes of VT linked to heart scarring. Researchers will check if the procedure is safe and if it can stop VT from happening again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTRICULAR TACHYCARDIA (VT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Texas Cardiac Arrhythmia Research Foundation
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sphere-9 catheter and Affera ablation system (device)
What this could lead to
If successful, this could provide a new, more effective way to treat ventricular tachycardia by precisely destroying the heart tissue causing dangerous rhythms.
What could go wrong
This is an early feasibility study with only 60 participants, so results may not apply to everyone. There are risks of serious complications like heart or lung problems from the procedure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.